Startseite>>Signaling Pathways>> Angiogenesis>> Integrin>>Egaptivon pegol sodium

Egaptivon pegol sodium

Katalog-Nr.GC70986

Egaptivon pegol sodium ist ein Aptamer, das die Bindung des von Willebrand-Faktors (VWF) an GPIb-Rezeptoren blockiert.

Products are for research use only. Not for human use. We do not sell to patients.

Egaptivon pegol sodium Chemische Struktur

Größe Preis Lagerbestand Menge
1 mg
259,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Egaptivon pegol sodium is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol sodium has anti-thrombotic efficacy.

References:
[1]. Avdonin PP, Trufanov SK, Rybakova EY, Tsitrina AA, Goncharov NV, Avdonin PV. The Use of Fluorescently Labeled ARC1779 Aptamer for Assessing the Effect of H2O2 on von Willebrand Factor Exocytosis. Biochemistry (Mosc). 2021;86(2):123-131.
[2]. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knöbl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;105(3):545-552.
[3]. Spiel AO, Mayr FB, Ladani N, et al. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets. 2009;20(5):334-340.

Bewertungen

Review for Egaptivon pegol sodium

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Egaptivon pegol sodium

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.